Qsymia generic
Qsymia is an anti-obesity medication owned by Vivus, which was first authorized for market use on 17 July, 2012. It contains two active ingredients: Phentermine Hydrochloride and Topiramate. These ingredients work effectively together to aid in weight management, including effecting weight loss, treating obesity, and treating overweight. This drug is available in an extended-release oral capsule dosage form. Qsymia holds a total of 6 patents.
When will Qsymia generic be available?
Qsymia's generic would be commercially available after its last patent expires on 14 June, 2029. However, this does not mean that Qsymia's generic will be immediately available after this date, as factors such as FDA approval, production, distribution, and sales can affect the availability of the generic version. Therefore, it is not accurate to give an exact date for the release of Qsymia generic.
Qsymia uses
Qsymia is primarily used for weight management. Its two active ingredients, Phentermine Hydrochloride and Topiramate, contribute significantly to its efficacy. Phentermine Hydrochloride is a type of anorectic or appetite suppressant which aids in weight loss by altering certain neurotransmitters in the brain which decrease appetite. On the other hand, Topiramate is a type of anticonvulsant or anti-epileptic drug which works to increase feelings of fullness, make your taste less appealing, and increase your body's ability to burn calories.
Qsymia patent expiration
Qsymia has six drug patents. The last patent of Qsymia, titled 'Escalating dosing regimen for effecting weight loss and treating obesity,' will expire on 14 June, 2029. Below is the detailed information about the patents: